| 7.87 0.3 (3.96%) | 10-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.07 | 1-year : | 11.77 |
| Resists | First : | 8.63 | Second : | 10.07 |
| Pivot price | 8.07  |
|||
| Supports | First : | 7.22 | Second : | 6.36 |
| MAs | MA(5) : | 7.8 |
MA(20) : | 8.02 |
| MA(100) : | 6.88 |
MA(250) : | 7.19 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 28.5 |
D(3) : | 29.3 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 10.41 | Low : | 5.24 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DMAC ] has closed above bottom band by 33.0%. Bollinger Bands are 26.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.1 - 8.14 | 8.14 - 8.18 |
| Low: | 7.42 - 7.48 | 7.48 - 7.53 |
| Close: | 7.48 - 7.57 | 7.57 - 7.64 |
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Mon, 19 Oct 2026
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - BioSpace
Thu, 24 Sep 2026
DiaMedica Therapeutics (NasdaqCM:DMAC) Stock Forecast & Analyst Predictions - Simply Wall Street
Tue, 22 Sep 2026
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely - Simply Wall Street
Tue, 08 Sep 2026
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - qz.com
Thu, 13 Aug 2026
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy - Yahoo Finance
Tue, 11 Aug 2026
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 27.8 (%) |
| Held by Institutions | 40.9 (%) |
| Shares Short | 5,580 (K) |
| Shares Short P.Month | 5,390 (K) |
| EPS | -0.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -64.2 % |
| Return on Equity (ttm) | -114.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -10.99 |
| PEG Ratio | 0 |
| Price to Book value | 11.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|